Teriparatide Promotes Bone Healing in Medication-Related Osteonecrosis of the Jaw: A Placebo-Controlled, Randomized Trial

What Was Tested

This randomized controlled trial paper looks at Teriparatide.

Who Took Part

The study group was 34 participants.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

Participants were observed for 12 months, with primary outcomes that included the clinical and radiologic resolution of MRONJ lesions.

How the Study Was Run

The design is described as randomized, double-blind and placebo-controlled.

The participants were allocated by chance, so the Teriparatide group and the comparison group should start out alike.

Neither the participants nor the staff measuring them knew who was on Teriparatide, so expectations could not easily colour the readings.

Some participants received a placebo instead of Teriparatide, giving a reference point.

A time span of 12 months appears in the methods.

Secondary outcomes included osteoblastic responses as measured biochemically and radiologically and changes in quality of life.

What Was Measured

The subject headings attached to it are Bisphosphonate-Associated Osteonecrosis of the Jaw, Bone Density Conservation Agents, Denosumab, Jaw, Teriparatide, Victoria and Wound Healing.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Teriparatide in 34 participants over 12 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2020 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology), a journal based in United States.

More context: the Teriparatide compound page, all human trials.